ADAlejandro Duque

Alejandro Duque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alejandro Duque has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Percentages of Effector Memory T Cells in Peripheral Blood Associated With Non‐Infectious Comorbidities in Common Variable Immunodeficiency Disorders

    by Jesús A. Álvarez‐Álvarez, Estefanía Vásquez‐Echeverri, Isaura P. Sánchez, Sebastián Gutierrez Hincapié, Alejandro Gallon Duque, Rubén D. Gómez‐Arias, Julio C. Orrego Arango, José L. Franco, Claudia M. Trujillo‐Vargas

    Common variable immunodeficiency disorders (CVID) are characterized by hypogammaglobulinemia and increased susceptibility to infections. However, non‐infectious comorbidities (NICM) are also frequent manifestations of the disease. We search for distinctive immunophenotypes in CVID patients with NICM. Data were obtained from the clinical records and laboratory analyses of 42 CVID patients. Descriptive statistics, median comparisons, bivariate and multivariate analysis were performed. Median comparison of the immunological variables among patients with or without NICM revealed significant decreased levels of serum IgG, percentages of naïve CD4+ and CD8+ T cells, total B cells and CD56dim NK cells in peripheral blood from CVID patients with NICM together with an increase in the percentages of effector memory (EM) CD4+ and terminally differentiated effector memory (EMRA) CD8+ T cells. By using logistic regressions, we determined the likelihood of exhibiting blood immunological abnormalities in patients with NICM vs. those without NICM. Finally, discriminant analyses and ROC curves established that percentages of CD4+ EM T cells and CD8+ EMRA T cells > 47.4% and 40.2% from the total CD4+ or CD8+ T cells, respectively, might be associated with NICM in CVID. These differences were also observed in CVID patients with Polyclonal lymphocytic infiltration. These data suggest subpopulations of effector T cells as potential biomarkers of NICM in CVID. Prospective studies are needed to determine the usefulness of our findings in the prognosis of CVID.


  • Open Access

    Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies

    by Swetha Raman, Melissa Beilschmidt, Minh To, Kevin Lin, Francine Lui, Yazen Jmeian, Mark Ng, Minerva Fernandez, Ying Fu, Keith Mascall, et al.

    Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.


  • Open Access

    A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations

    by Allison M. L. Nixon, Alejandro Duque, Nicholas Yelle, Megan McLaughlin, Sadegh Davoudi, Nicolas M. Pedley, Jennifer Haynes, Kevin R. Brown, James Pan, Traver Hart, et al.

    Cell surface antigen discovery is of great interest for biomedical research both for isolation of rare cell populations and therapeutic targeting. We developed a rapid, cost-effective, fully in vitro technology which facilities the simultaneous target discovery and human antibody generation on the surface of virtually any cell population of interest. We apply our technique to human colorectal cancer-initiating cells (CICs) and identify hundreds of unique human antibodies. We characterized the top three antibody candidates targeting these CICs and identify their protein targets as integrin α7 (ITGA7), HLA-A1 and integrin β6 (ITGB6). We demonstrate that these antibodies can be used to isolate self-renewing colorectal CICs, and that the integrin α7 antibody can prospectively identify glioblastoma brain tumor initiating cells as well as human muscle stem cells. We also demonstrate that genetic ablation of integrin β6 impedes colorectal CIC function. The methodology can be readily applied to other cell populations including stem cells, cancer, or immune cells to facilitate the rapid identification of novel targets and simultaneous generation of potent and specific antibodies with therapeutic potential.